Top

Cancer Immunology, Immunotherapy

Published in:

01-08-2002 | Review

Immature myeloid cells and cancer-associated immune suppression

Authors: Sergei Kusmartsev, Dmitry I. Gabrilovich

Published in: Cancer Immunology, Immunotherapy | Issue 6/2002

Title: Immature myeloid cells and cancer-associated immune suppression
Authors: Sergei Kusmartsev
Dmitry I. Gabrilovich
Publication date: 01-08-2002
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 6/2002
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-002-0280-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 6/2002

Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines

Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses

Linkage of CD40L to a self-tumor antigen enhances the antitumor immune responses of dendritic cell-based treatment

Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell–leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination

Hsp110 over-expression increases the immunogenicity of the murine CT26 colon tumor

Immunogenicity of WT-1 peptides

Keynote webinar | Spotlight on antibody–drug conjugates in cancer